TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) shares traded down 8.9% during trading on Friday . The stock traded as low as $68.01 and last traded at $70.7980. Approximately 497,424 shares were traded during trading, a decline of 54% from the average session volume of 1,080,917 shares. The stock had previously closed at $77.75.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the stock. TD Cowen reduced their price objective on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Piper Sandler reduced their price target on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. Stifel Nicolaus raised their price objective on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Finally, Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $134.50.
View Our Latest Stock Report on TransMedics Group
TransMedics Group Price Performance
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The business had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.TransMedics Group’s revenue was up 21.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.70 earnings per share. On average, analysts forecast that TransMedics Group, Inc. will post 1.98 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.
Hedge Funds Weigh In On TransMedics Group
Several institutional investors have recently added to or reduced their stakes in TMDX. Royal Bank of Canada boosted its holdings in shares of TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after buying an additional 938 shares in the last quarter. Finally, M&T Bank Corp bought a new position in shares of TransMedics Group in the second quarter valued at about $209,000. 99.67% of the stock is owned by institutional investors.
TransMedics Group Company Profile
TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.
TransMedics currently markets two commercially available OCS platforms.
Read More
- Five stocks we like better than TransMedics Group
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
- Data Center Delays Create Opportunity in These 3 Stocks
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
